Synergistic Effect of Eicosapentaenoic Acid on Antiproliferative Action of Anticancer Drugs in a Cancer Cell Line Model.
| Autor: | Ogo A; Department of Clinical Nutrition, Faculty of Health Science and Technology, Kawasaki University of Medical Science, Kurashiki, Japan., Miyake S; Department of Clinical Nutrition, Faculty of Health Science and Technology, Kawasaki University of Medical Science, Kurashiki, Japan., Kubota H; Department of Digestive Surgery, Kawasaki Medical School, Kurashiki, Japan., Higashida M; Department of Digestive Surgery, Kawasaki Medical School, Kurashiki, Japan., Matsumoto H; Mitsugi General Hospital, Onomichi, Japan., Teramoto F; Department of Clinical Nutrition, Faculty of Health Science and Technology, Kawasaki University of Medical Science, Kurashiki, Japan., Hirai T; Department of Clinical Nutrition, Faculty of Health Science and Technology, Kawasaki University of Medical Science, Kurashiki, Japan. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Annals of nutrition & metabolism [Ann Nutr Metab] 2017; Vol. 71 (3-4), pp. 247-252. Date of Electronic Publication: 2017 Nov 14. |
| DOI: | 10.1159/000484618 |
| Abstrakt: | Background/aims: It has been found experimentally and clinically that eicosapentaenoic acid (EPA) exerts an anticancer effect and that it has a minimal adverse event profile relative to other anticancer drugs. Any synergy between EPA and other anticancer drugs could be of therapeutic relevance, especially in elderly or high-risk patients. Therefore, we investigated the synergism between anticancer drugs and EPA experimentally. Methods: EPA was coadministered in vitro with various anticancer drugs (paclitaxel, docetaxel, 5-fluorouracil and cis-diamminedichloridoplatinum[II]) to TE-1 cells, which were derived from human esophageal cancer tumors. Cell proliferation was measured by the water soluble tetrazolium-1 method. Result: Sub-threshold concentrations of EPA, which alone produced no anticancer effect, caused a synergistic suppressive effect on TE-1 cell proliferation when combined with other anticancer agents. Conclusion: Coadministration of EPA with other anticancer drugs may represent a new therapeutic paradigm offering a reduced side effect profile. (© 2017 S. Karger AG, Basel.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|